In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly & Co. said Tuesday that patients can ... executive vice president and president of Lilly Cardiometabolic Health and ...
Eli Lilly (LLY) has announced it will make lower ... options they can rely on,” Patrik Jonsson, president of Lilly USA, said about the partnership in a press release. Zepbound belongs to the ...
Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...
Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro ... Jr. is a trending news reporter for USA TODAY. Reach him at fernando.cervantes@ ...
Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...
Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or tirzepatide, is the first and ...
COLORADO SPRINGS, Colo., Jan. 7, 2025 /PRNewswire/ -- Junior Achievement USA announced today that it has received a $22.5 million grant from Lilly Endowment Inc. to enhance existing curricula and ...
On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep apnea medication. Zepbound or Tirzepatide is an injectable drug that the ...
NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% ...